Protagonist Therapeutics logo

Protagonist TherapeuticsNASDAQ: PTGX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

11 August 2016

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$2.51 B
-13%vs. 3y high
83%vs. sector
-13%vs. 3y high
25%vs. sector
-40%vs. 3y high
80%vs. sector
-88%vs. 3y high
72%vs. sector

Price

regular market | 13 min ago
$42.13+$1.48(+3.64%)

Dividend

No data over the past 3 years
$4.67 M$61.17 M
$4.67 M-$33.21 M

Analysts recommendations

Institutional Ownership

PTGX Latest News

Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate
accesswire.com19 November 2024 Sentiment: POSITIVE

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral peptide IL-17 antagonist development candidate and to share in vitro and pre-clinical proof-of-concept study results. Conference Call and Webcast Details The dial-in numbers for Protagonist's investor update on Thursday, November 21st at 4:30 pm ET are: US-based Investors: 1-877-407-0752International Investors: 1-201-389-0912Conference Call ID: 13750274 The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1698744&tp_key=f6482f31c0 A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.

Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know
zacks.com13 November 2024 Sentiment: POSITIVE

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor
accesswire.com31 July 2024 Sentiment: POSITIVE

Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE / July 31, 2024 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Newman Yeilding, M.D. to the role of Chief Scientific Advisor, effective August 1, 2024.

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable
zacks.com18 July 2024 Sentiment: POSITIVE

If you are looking for stocks that are well positioned to maintain their recent uptrend, Protagonist Therapeutics (PTGX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Zacks Investment Research05 April 2024 Sentiment: POSITIVE

Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
Zacks Investment Research18 March 2024 Sentiment: POSITIVE

The consensus price target hints at a 48.4% upside potential for Protagonist Therapeutics (PTGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?
Zacks Investment Research01 March 2024 Sentiment: POSITIVE

Protagonist Therapeutics (PTGX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice
Zacks Investment Research01 March 2024 Sentiment: POSITIVE

Does Protagonist Therapeutics (PTGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research01 March 2024 Sentiment: POSITIVE

Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade
Zacks Investment Research01 March 2024 Sentiment: POSITIVE

The average of price targets set by Wall Street analysts indicates a potential upside of 37.2% in Protagonist Therapeutics (PTGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • 1(current)

What type of business is Protagonist Therapeutics?

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

What sector is Protagonist Therapeutics in?

Protagonist Therapeutics is in the Healthcare sector

What industry is Protagonist Therapeutics in?

Protagonist Therapeutics is in the Biotechnology industry

What country is Protagonist Therapeutics from?

Protagonist Therapeutics is headquartered in United States

When did Protagonist Therapeutics go public?

Protagonist Therapeutics initial public offering (IPO) was on 11 August 2016

What is Protagonist Therapeutics website?

https://www.protagonist-inc.com

Is Protagonist Therapeutics in the S&P 500?

No, Protagonist Therapeutics is not included in the S&P 500 index

Is Protagonist Therapeutics in the NASDAQ 100?

No, Protagonist Therapeutics is not included in the NASDAQ 100 index

Is Protagonist Therapeutics in the Dow Jones?

No, Protagonist Therapeutics is not included in the Dow Jones index

When was Protagonist Therapeutics the previous earnings report?

No data

When does Protagonist Therapeutics earnings report?

The next expected earnings date for Protagonist Therapeutics is 27 February 2025